356 related articles for article (PubMed ID: 15118266)
1. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction.
Takeuchi T; Tsutsumi O; Ikezuki Y; Takai Y; Taketani Y
Endocr J; 2004 Apr; 51(2):165-9. PubMed ID: 15118266
[TBL] [Abstract][Full Text] [Related]
2. Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels.
Takeuchi T; Tsutsumi O
Biochem Biophys Res Commun; 2002 Feb; 291(1):76-8. PubMed ID: 11829464
[TBL] [Abstract][Full Text] [Related]
3. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS.
Kandaraki E; Chatzigeorgiou A; Livadas S; Palioura E; Economou F; Koutsilieris M; Palimeri S; Panidis D; Diamanti-Kandarakis E
J Clin Endocrinol Metab; 2011 Mar; 96(3):E480-4. PubMed ID: 21193545
[TBL] [Abstract][Full Text] [Related]
4. Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome.
Konieczna A; Rachoń D; Owczarek K; Kubica P; Kowalewska A; Kudłak B; Wasik A; Namieśnik J
Reprod Toxicol; 2018 Dec; 82():32-37. PubMed ID: 30266220
[TBL] [Abstract][Full Text] [Related]
5. [Androgen and 17-hydroxyprogesterone concentrations in blood serum versus menstrual patterns in women with polycystic ovary syndrome (PCOS)].
Rudnicka E; Kunicki M; Radowicki S
Ginekol Pol; 2010 Oct; 81(10):745-9. PubMed ID: 21117302
[TBL] [Abstract][Full Text] [Related]
6. Urinary bisphenol A in women with polycystic ovary syndrome - a possible suppressive effect on steroidogenesis?
Lazúrová Z; Figurová J; Hubková B; Mašlanková J; Lazúrová I
Horm Mol Biol Clin Investig; 2021 Jun; 42(3):303-309. PubMed ID: 34118794
[TBL] [Abstract][Full Text] [Related]
7. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
8. The endocrine disruptor bisphenol A may play a role in the aetiopathogenesis of polycystic ovary syndrome in adolescent girls.
Akın L; Kendirci M; Narin F; Kurtoglu S; Saraymen R; Kondolot M; Koçak S; Elmali F
Acta Paediatr; 2015 Apr; 104(4):e171-7. PubMed ID: 25469562
[TBL] [Abstract][Full Text] [Related]
9. Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of the link between polycystic ovary syndrome and functional hypothalamic amenorrhea.
Carmina E; Fruzzetti F; Lobo RA
Am J Obstet Gynecol; 2016 Jun; 214(6):714.e1-6. PubMed ID: 26767792
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and endocrine effects of bisphenol A exposure in market seller women with polycystic ovary syndrome.
Vahedi M; Saeedi A; Poorbaghi SL; Sepehrimanesh M; Fattahi M
Environ Sci Pollut Res Int; 2016 Dec; 23(23):23546-23550. PubMed ID: 27614642
[TBL] [Abstract][Full Text] [Related]
11. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
12. The association between the environmental endocrine disruptor bisphenol A and polycystic ovary syndrome: a systematic review and meta-analysis.
Hu Y; Wen S; Yuan D; Peng L; Zeng R; Yang Z; Liu Q; Xu L; Kang D
Gynecol Endocrinol; 2018 May; 34(5):370-377. PubMed ID: 29191127
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
[TBL] [Abstract][Full Text] [Related]
14. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.
Eldar-Geva T; Spitz IM; Groome NP; Margalioth EJ; Homburg R
Hum Reprod; 2001 Dec; 16(12):2552-6. PubMed ID: 11726573
[TBL] [Abstract][Full Text] [Related]
15. Examination of angiopoietin-like protein 4, neuropeptide Y, omentin-1 levels of obese and non-obese patients with polycystic ovary syndrome.
Güneş M; Bukan N
Gynecol Endocrinol; 2015; 31(11):903-6. PubMed ID: 26291814
[TBL] [Abstract][Full Text] [Related]
16. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.
Studen KB; Sebestjen M; Pfeifer M; Prezelj J
Eur J Endocrinol; 2011 Mar; 164(3):389-95. PubMed ID: 21156647
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
[TBL] [Abstract][Full Text] [Related]
18. The effect of weight loss on inflammation in obese women with polycystic ovary syndrome.
Olszanecka-Glinianowicz M; Zahorska-Markiewicz B; Kocełak P; Janowska J; Semik-Grabarczyk E
Endokrynol Pol; 2008; 59(1):13-7. PubMed ID: 18335395
[TBL] [Abstract][Full Text] [Related]
19. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
[TBL] [Abstract][Full Text] [Related]
20. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
Olszanecka-Glinianowicz M; Banaś M; Zahorska-Markiewicz B; Kuglin D; Mokrzycka J; Mentel A
Endokrynol Pol; 2005; 56(6):921-6. PubMed ID: 16821212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
